Zobrazeno 1 - 10
of 47
pro vyhledávání: '"Antonio Scalfari"'
Autor:
Gavin Giovannoni, Helen L. Ford, Klaus Schmierer, Rod Middleton, Andrea M. Stennett, Ian Pomeroy, Leonora Fisniku, Antonio Scalfari, Colin Bannon, Ruth Stross, Sarah Hughes, Adam Williams, Samantha Josephs, Charlie Peel, Agne Straukiene
Publikováno v:
Frontiers in Neurology, Vol 14 (2024)
Lifestyle and environmental factors are key determinants in disease causality and progression in neurological conditions, including multiple sclerosis (MS). Lack of exercise, poor diet, tobacco smoking, excessive alcohol intake, social determinants o
Externí odkaz:
https://doaj.org/article/133e454dbcd84b3099376eea535b61cd
Autor:
Gavin Giovannoni, Eli Silber, Ruth Dobson, Riffat Tanveer, Jade Harris, Tarunya Arun, Miriam Mattoscio, Ghaniah Hassan-Smith, Huw Morris, Rod Middleton, Emma Tallantyre, David Rog, Nikos Evangelou, Benjamin M Jacobs, Antonio Scalfari, Waqar Rashid, Helen L Ford, Charles A Mein, Stephen Sawcer, Cord Spilker, Bruno Gran, Martin O'Malley, Ashwini Nandoskar, Emeka Uzochukwu, Katila George, Sadid Hoque, Luisa Schalk, Angie Dunne, Charlotte Sellers, Elisa Visentin, Elizabeth Lindsey Bezzina, Eva Wozniak, Eve Sacre, Joan Bradley, Joshua Breedon, Judith Brooke, Karim L Kreft, Katherine Tuite Dalton, Maria Papachatzaki, Michelle Peter, Neisha Rhule, Nimisha Vinod, Outi Quinn, Ramya Shamji, Rashmi Kaimal, Rebecca Boulton, Roxanne Murray, Ruth Bellfield, Shakeelah Patel, Sonia Raj, Stephanie Gumus, Stephanie Mitchell, Tatiana Pogreban, Terri-Louise Brown, Thamanna Begum, Veronica Antoine
Publikováno v:
BMJ Open, Vol 13, Iss 5 (2023)
Purpose Genetic studies of multiple sclerosis (MS) susceptibility and severity have focused on populations of European ancestry. Studying MS genetics in other ancestral groups is necessary to determine the generalisability of these findings. The gene
Externí odkaz:
https://doaj.org/article/dfaa829aa3244981a9b0642497517dd8
Autor:
Gavin Giovannoni, Veronica Popescu, Jens Wuerfel, Kerstin Hellwig, Ellen Iacobaeus, Michael B. Jensen, José Manuel García-Domínguez, Livia Sousa, Nicola De Rossi, Raymond Hupperts, Giuseppe Fenu, Benedetta Bodini, Hanna-Maija Kuusisto, Bruno Stankoff, Jan Lycke, Laura Airas, Cristina Granziera, Antonio Scalfari
Publikováno v:
Therapeutic Advances in Neurological Disorders, Vol 15 (2022)
Using a philosophical approach or deductive reasoning, we challenge the dominant clinico-radiological worldview that defines multiple sclerosis (MS) as a focal inflammatory disease of the central nervous system (CNS). We provide a range of evidence t
Externí odkaz:
https://doaj.org/article/4459984229244fd5b40a35ceb0a2daa4
Autor:
Kimberley Allen-Philbey, Stefania De Trane, Zhifeng Mao, Cesar Álvarez-González, Joela Mathews, Amy MacDougall, Andrea Stennett, Xia Zhou, Ozlem Yildiz, Ashok Adams, Lucia Bianchi, Camilla Blain, Christine Chapman, Karen Chung, Cris S Constantinescu, Catherine Dalton, Rachel A Farrell, Leonora Fisniku, Helen Ford, Bruno Gran, Jeremy Hobart, Zhaleh Khaleeli, Miriam Mattoscio, Sue Pavitt, Owen Pearson, Luca Peruzzotti-Jametti, Antonio Scalfari, Basil Sharrack, Eli Silber, Emma C Tallantyre, Stewart Webb, Benjamin P Turner, Monica Marta, Sharmilee Gnanapavan, Gunnar Juliusson, Gavin Giovannoni, David Baker, Klaus Schmierer
Publikováno v:
Therapeutic Advances in Neurological Disorders, Vol 14 (2021)
Objective: To report on safety and effectiveness of subcutaneous cladribine (Litak ® ) in multiple sclerosis (MS) patients. Methods: Litak ® was offered to MS-patients irrespective of disease course. Litak ® 10 mg was administered for 3–4 days d
Externí odkaz:
https://doaj.org/article/bfd4d711187c4be1bbc0bfb3a0440750
Autor:
Massimiliano Calabrese, Richard Reynolds, Roberta Magliozzi, Marco Castellaro, Aldo Morra, Antonio Scalfari, Gabriele Farina, Chiara Romualdi, Alberto Gajofatto, Marco Pitteri, Maria Donata Benedetti, Salvatore Monaco
Publikováno v:
PLoS ONE, Vol 10, Iss 8, p e0135428 (2015)
Both gray-matter (GM) atrophy and lesions occur from the earliest stages of Multiple Sclerosis (MS) and are one of the major determinants of long-term clinical outcomes. Nevertheless, the relationship between focal and diffuse GM damage has not been
Externí odkaz:
https://doaj.org/article/635159500036462d92d4c742db226fb7
Autor:
Francesca Bagnato, Antonio Scalfari, Jiwon Oh, Laura Airas, Stefan Bittner, Massimiliano Calabrese, Jose Manuel Garcia Dominguez, Cristina Granziera, Benjamin Greenberg, Kerstin Hellwig, Zsolt Laszlo Illes, Jan Lycke, Anthony Traboulsee, Veronica Popescu, Gavin Giovannoni
Publikováno v:
Wednesday, April 26.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::35a3258f5a67ed5be5008761345bf96c
https://doi.org/10.1212/wnl.0000000000203661
https://doi.org/10.1212/wnl.0000000000203661
Autor:
Paul M. Matthews, Digant Gupta, Deepali Mittal, Wenjia Bai, Antonio Scalfari, Kevin G. Pollock, Vishal Sharma, Nathan Hill
Publikováno v:
Multiple Sclerosis and Related Disorders. 74:104714
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::02fa73529043745ba404c84f3b304ccc
https://doi.org/10.1016/j.msard.2023.104714
https://doi.org/10.1016/j.msard.2023.104714
Autor:
Antonio Scalfari, Chiara Romualdi, Anna Isabella Pisani, Francesco Crescenzo, Massimiliano Calabrese
Publikováno v:
European Journal of Neurology
Background At patient-level, the prognostic value of several features that are known to be associated with an increased risk of converting from relapsing remitting (RR) to secondary phase (SP) multiple sclerosis (MS), remain limited. Methods Among 26
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e4b6daf61913980076852c521086c009
http://europepmc.org/articles/PMC8360167
http://europepmc.org/articles/PMC8360167
Autor:
Tobias Ruck, Leoni Rolfes, Antonio Scalfari, Luisa Klotz, Steffen Pfeuffer, Sven G. Meuth, Refik Pul, Brigitte Wildemann, Marc Pawlitzki, Catharina Korsukewitz, Christoph Kleinschnitz, Heinz Wiendl
Publikováno v:
Journal of Neurology, Neurosurgery & Psychiatry. 92:1007-1013
ObjectivesAlemtuzumab is effective in patients with active multiple sclerosis but has a complex safety profile, including the development of secondary autoimmunity. Most of patients enrolled in randomised clinical trials with alemtuzumab were either
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e00cbb20b3e93cf9d4244cd7c32e58ad
https://doi.org/10.1136/jnnp-2020-325304
https://doi.org/10.1136/jnnp-2020-325304